Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The purpose of this clinical study is to prove that the test drug (TJO-087) is not clinically inferior to the control drug after 32 weeks of administration to patients with suppressed tear production due to moderate or severe dry eye syndrome.
Epistemonikos ID: 810c12b0320895902b8a086d0fef7d6e4b71fd39
First added on: May 10, 2024